| Inclusion Criteria: | 1) This study is open to previously treated patients with locally advanced or metastatic NSCLC, locally advanced or metastatic breast cancer and metastatic prostate cancer for whom Taxotere is an appropriate treatment. This includes breast cancer patients after failure of prior chemotherapy, NSCLC patients after failure of prior platinum-based chemotherapy, and prostate cancer patients who are hormone refractory. There is no limit on the number of prior chemotherapy regimens, provided all other eligibility criteria are met.
2) Measurable or evaluable (non-measurable) disease
3) ECOG performance status 0 - 2
4) Age >/= 18 years
5) Prior docetaxel therapy is permitted.
6) If female, neither pregant (negative pregnancy test) nor lactating
7) If of child-bearing potential, must be able and agree to use adequate contraception
8) Concomitant disease: no respiratory insufficiency requiring oxygen therapy; no angina at rest; no myocardial infarction in previous 3 months; no life-threatening ventricular arrhythmias; no current or past history of congestive heart failure (patients with a past history or current history of any heart disease including: aneurysms, arrhythmias, atherosclerotic coronary artery disease, cardiomyopathies, heart failure of any cause, pericardial diseases, valvular heart diseases, infectious heart diseases,
9) (contingued from Inclusion #8) inflammatory heart disease, congenital heart disease, myocardial infarction, angina, abnormal EKG, or systemic atherosclerotic disease such as stroke or TIA shall have a MUGA scan with an ejection fraction within the normal limits of the testing institution.
10) No other concurrent active malignancy requiring treatment
11) Off all anticancer therapy for greater than or equal to 4 weeks. This includes surgery, chemotherapy, and radiation.
12) Prior radiotherapy is permitted, but only if to less than an estimated 25% of the bone marrow.
13) No infection requiring parenteral antibiotic therapy concurrent with the study drug
14) No effusions or chronic fluid retention
15) Patients must be off systemic steroids for a minimum of 2 weeks, except in the case of patients with prostate cancer who will be treated with prednisone 5 mg po bid during the protocol therapy. Inhaled steroids are allowed. The standard prophylactic corticosteroid therapy for the prevention of acute reactions to docetaxel will also be used.
16) Lab values within the following criteria: hgb >/= 9 gm/dL; ANC >/= 1,500/mm^3; plt >/= 100,000/mm^3; creatinine </= 1.5 x upper limit of normal (ULN); bilirubin </= ULN; AST, ALT </= 1.5 x ULN; alkaline phosphatase </= 1.5 x ULN; G6PD >/= lower limit of normal
17) Able to render informed consent and to follow protocol requirements |